Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends

  • Helen Baldomero
  • Mahmoud Aljurf
  • Syed Z A Zaidi
  • Shahrukh K Hashmi
  • Ardeshir Ghavamzadeh
  • Alaa Elhaddad
  • Rose-Marie Hamladji
  • Parvez Ahmed
  • Lamia Torjemane
  • Miguel Abboud
  • Abdelghani Tbakhi
  • Murtadha Al Khabori
  • Asma El Quessar
  • Nosa Bazuaye
  • Mohamed Amine Bekadja
  • Salman Adil
  • Omar Fahmy
  • Mani Ramzi
  • Ahmed Ibrahim
  • Amal Alseraihy
  • Nour Ben Abdejalil
  • Mahmoud Sarhan
  • Mohammed Al Huneini
  • Lahoucine Mahmal
  • Hassan ElSolh
  • Fazal Hussain
  • Amr Nassar
  • Hani Al-Hashmi
  • Amir Ali Hamidieh
  • Marcelo Pasquini
  • Yoshihisa Kodera
  • Nicolaus Kröger
  • Mohamed Mohty
  • Gregorio Jaimovich
  • Juliana Martinez Rolon
  • Kristjan Paulson
  • Hildegard Greinix
  • Daniel Weisdorf
  • Mary Horowitz
  • José Nunez
  • Alois Gratwohl
  • Jacob Passweg
  • Mickey Koh
  • Jeff Szer
  • Dietger Niederwieser
  • Nicolas Novitzky
  • East-Mediterranean (EMBMT) and African (AfBMT) Blood and Marrow Transplantation Groups and the Worldwide Network for Blood and Marrow Transplantation (WBMT)

Abstract

Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared to autologous HSCT, an almost exclusive use of family donors, including haploidentical family donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in HSCT for hemoglobinopathies from 2006 to 2013 (72 per year) in the AFR/EMRO region. This reflects the specific role of HSCT for these disease categories with high prevalence and incidence in the AFR/EMRO region. This report provides information for the competent authorities to foster adequate infrastructure. It urges transplant organization to optimize their cooperation.

Bibliographical data

Original languageEnglish
ISSN0268-3369
DOIs
Publication statusPublished - 03.2019
PubMed 30082852